Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.

about

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.

Item

http://www.wikidata.org/entity/Q40045651

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Efficacy and Safety of Human I ...... Prospective, Open-Label Study.

@en

type

Item

label

Efficacy and Safety of Human I ...... Prospective, Open-Label Study.

@en

prefLabel

Efficacy and Safety of Human I ...... Prospective, Open-Label Study.

@en

P1476

Efficacy and Safety of Human I ...... Prospective, Open-Label Study.

@en

P2093

Ai Lan Kobayashi

http://www.w3.org/2001/XMLSchema#string

Alan P Knutsen

http://www.w3.org/2001/XMLSchema#string

Anna Pituch-Noworolska

http://www.w3.org/2001/XMLSchema#string

Barbara Pyringer

http://www.w3.org/2001/XMLSchema#string

Grazyna Pulka

http://www.w3.org/2001/XMLSchema#string

Hans D Ochs

http://www.w3.org/2001/XMLSchema#string

Isaac R Melamed

http://www.w3.org/2001/XMLSchema#string

James N Moy

http://www.w3.org/2001/XMLSchema#string

Magdalena Strach

http://www.w3.org/2001/XMLSchema#string

Michael Borte

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015.

Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency--lessons learned from monogenic disorders in mice and men

Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.

Primary immunodeficiencies: a rapidly evolving story.

Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.

Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.

Primary immunodeficiency diseases and cancer: the immunodeficiency-cancer registry.

Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.

P2888

s10875-017-0424-4

P31

scholarly article

P356

10.1007/S10875-017-0424-4

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090920374

http://www.w3.org/2001/XMLSchema#string

P698

28755067

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

5554470

http://www.w3.org/2001/XMLSchema#string